Jefferies London: Terns' CEO Amy Burroughs previews the company's upcoming ASH presentation for the allosteric BCR::ABL1 inhibitor tern-701 in relapsed/refractory cml
- Nov 19, 2025
- 1 min read
The data has been accepted for an oral presentation on Monday, December 8 and will be followed by a company webcast with more info.
Coverage brought to you by















.png)

